Metastatic Solid Tumors to Bone

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 374-378

  Mundy, Gregory R ^a   Sterling, Julie A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

And metastasis to bone; Osteoblastic tumors; Osteolytic tumors

Indexed keywords

EID: 79251546968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch79     Document Type: Chapter

References (50)

1. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR 1996 Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544-1549.
2. Gallwitz WE, Guise TA, Mundy GR 2002 Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest 110:1559-1572.
3. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR 1986 Scanning electron microscopy in bone pathology: Review of methods, potential and applications. Scan Electron Microsc Pt 4:1537-1554.
4. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA 1999 TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206.
5. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K 2001 Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61:1637-1644.
6. Martin TJ, Gillespie MT 2001 Receptor activator of nuclear factor kappa B ligand (RANKL): Another link between breast and bone. Trends Endocrinol Metab W.2-A.
7. Kitazawa S, Kitazawa R 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228-236.
8. Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, Story B, Zhao M, Mundy GR 2006 The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 66:7548-7553.
9. Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR 1997 Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ib-andronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:2509-2517.
10. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T 1996 E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56:4063-1070.
11. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA 2004 Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939.
12. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T 1992 A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 52:5395-5399.
13. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ 2005 Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65:11001-11009.
14. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ 2003 Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28-37.
15. Bendre M, Gaddy D, Nicholas RW, Suva LJ 2003 Breast cancer metastasis to bone: It is not all about PTHrP. Clin Orthop 415(Suppl):S39-S45.
16. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E 2001 Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18-24.
17. McDermott RS, Deneux L, Mosseri V, Vedrenne J, Clough K, Fourquet A, Rodriguez J, Cosset JM, Sastre X, Beuzeboc P, Pouil-lart P, Scholl SM 2002 Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw 13:121-127.
18. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS 2005 Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102:1454-1459.
19. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS 2006 Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25:589-600.
20. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB 2005 The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591.
21. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M 2005 MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7:485-196.
22. Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE, Baron R 1982 Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: Uncoupling of bone cell activity. J Clin Endocrinol Metab 55:219-227.
23. Mohammad KS, Stebbins EG, Niewolna M, McKenna CR, Walton H, Peng XH, Li G, Murphy A, Chakravarty S, Higgins LS. Wong DH, Guise TA 2006 TGF-beta signaling blockade reduces osteolytic bone metastases and enchances bone mass. Cancer Treat Rev 32(Suppl 3):S29.
24. Guise TA, Stebbins EG, Mohammad KS, Niewolna M, McKenna CR, Mison AP, Li G, Schimmoller F, Murphy A, Chakravarty S 2006 Blocking TBF-beta signaling in breast cancer: Effects on bone and bone metastases. Cancer Treat Rev 32:S26.
25. Takeuchi K, Abe M, Hiasa M, Kitazoe K, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T 2006 A TGF-beta receptor kinase inhibitor, restores bone formation which disrupts myeloma-induced microenvironment. Cancer Treat Rev 32(Suppl 3):S25.
26. Epstein J 2006 Myeloma, bone, and disease control. Cancer Treat Rev 32(Suppl 3):S23.
27. Matsumoto T, Abe M 2006 Myeloma bone disease: A vicious cycle by interactions between myeloma cells and bone marrow cells. Cancer Treat Rev 32(Suppl 3):S23.
28. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR. Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA 2003 A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100:10954-10959.
29. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T 2002 Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62:917-923.
30. Hall CL, Kang S, MacDougald OA, Keller ET 2006 Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97:661-672.
31. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA 2007 Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21:486-198.
32. Kaplan RN, Rafii S, Lyden D 2006 Preparing the "soil": The premetastatic niche. Cancer Res 66:11089-11093.
33. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC 2004 Expansion of myeloid immune suppressor Gr+CDllb+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421.
34. Arguello F, Baggs RB, Frantz CW 1988 A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48:6876-6881.
35. Yoneda T 2000 Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5:75-81.
36. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T 2004 Zole-dronic acid inhibits visceral metastases in the 4Tl/luc mouse breast cancer model. Clin Cancer Res 10:4559-4567.
37. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M 2005 A mouse model of human breast cancer metastasis to human bone. Cancer Res 65:6130-6138.
38. Morrissey C, Kostenuik PJ, Brown LG, Vessella RL, Corey E 2007 Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer 7:148.
39. Marcelli C, Yates AJ, Mundy GR 1990 In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J Bone Miner Res 5:1087-1096.
40. Coleman RE 2001 Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176.
41. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A. Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791.
42. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T 1999 A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179-1181.
43. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS 2007 Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 99:1016-1024.
44. Marx RE. Stern D 2002 Oral and Maxillofacial Pathology: A Rationale for Treatment. Quintessence Publishing, Hanover Park, IL, USA.
45. American Dental Association Council on Scientific Affairs 2006 Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 137:1144-1150.
46. American Association of Oral and Maxillofacial Surgeons 2007 Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376.
47. Ruggiero SL, Fantasia J, Carlson E 2006 Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433-141.
48. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534.
49. Durie BG, Katz M, Crowley J 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102.
50. Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, Wood WI, Martin TJ 1988 Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest 82:1798-1802.